ACTG A5090

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。认知障碍是艾滋病毒感染的一种常见后遗症，可发展为痴呆症。HIV痴呆的基本特征是致残性认知障碍，通常伴有运动功能障碍和行为改变。两项司来吉兰的试点研究已经证明了小剂量司来吉兰的安全性，并建议改善HIV相关认知障碍患者的言语记忆和精神运动速度表现。本研究的目的是确定在HIV相关认知障碍患者中长期使用STS的安全性，并评估STS在治疗HIV相关认知障碍中的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cognitive impairement is a common sequela of HIV infection that can progress to dementia. The essential features of HIV dementia are disabling cognitive impairment, usually accompanied by motor dysfunction and behavioral change. Two pilot studies of selegiline have demonstrated safety for low dose selegiline and have suggested improvement in verbal memory and psychomotor speed performance in patients with HIV-associated cognitive impairment. The objective of this study is to determine the safety of long-term use of STS in subjects with HIV-associated cognitive impairment and to assess the efficacy of STS in the treatment of HIV-associated cognitive impairment.